PROSPECTIVE COMPARATIVE EFFECTIVENESS OF SITAGLIPTIN AND DAPAGLIFLOZIN IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS

Abstract

Type 2 Diabetes Mellitus is a chronic and advancing metabolic disease that shows the defining characteristic features of chronic hyperglycemia, raised risk of cardiovascular and microvascular outcomes. The latest oral anti-diabetic medications that have gained prevalence because of their better safety and efficacy evidence are dipeptidyl peptidase-4 (DPP-4) inhibitors Type and sodium-glucose co-transporter-2 (SGLT2) inhibitors. The safety and efficacy of dapagliflozin versus sitagliptin in patients with type 2 diabetes were systematically assessed. To determine and compare the impact of sitagliptin and dapagliflozin on the safety profile, glycemic control and a few clinical and demographic variables like age, gender, family history, and duration of diabetes. A total of 120 individuals with T2DM aged 25 to 70 years with HbA1c levels of 7% to 10% were chosen for this study. Patients were unbiasedly divided into two equal batches and received either dapagliflozin (n = 60) or sitagliptin (n = 60). Glycemic variables including fasting blood sugar (FBS), postprandial blood sugar (PPBS), and HbA1c levels were assessed at baseline and during follow-up. SPSS software package was used to execute the statistical analysis. Dapagliflozin was statistically more in therapeutic efficacy than in sitagliptin, while sitagliptin was more therapeutically effective in managing postprandial glucose levels. Dapagliflozin was more effective than sitagliptin in maintaining overall glycemic control and additional metabolic outcomes in patients with type 2 diabetes mellitus.